CTRI/2023/08/056828尚未招募3 期
Metoclopramide or dexamethasone, for prevention of delayed chemotherapy- induced nausea and vomiting after oxaliplatin based chemotherapy-a randomized controlled noninferiority trial - NI
no sponsor0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Eastern Cooperative Oncology Group performance status <3
- •Patients who are scheduled to receive Oxaliplatin based chemotherapy for treatment of a histologically confirmed solid malignancy.
- •Adequate bone marrow, hepatic and renal functions.
排除标准
- •Patients receiving radiotherapy within 2 weeks before initiation of chemotherapy or between days 1 and 8 after the administration of chemotherapy
- •Receipt of medication with antiemetic effect up to 48 hours before chemotherapy
- •Vomiting, retching, or nausea up to 48 hours before chemotherapy
- •Conditions such as intestinal obstruction, active peptic ulcer,hypercalcemia, uncontrolled diabetes mellitus(fasting blood sugar >125,or Postprandial Blood sugar >199), pheochromocytoma,brain or leptomeningeal metastases, parkinsonism,epilepsy, or psychiatric disorders.
- •Concurrent use of corticosteroids
- •Pregnant or nursing women
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate metoclopramide, dexamethasone or Aloxi for the prevention of nausea and vomiting occuring more than 24 hours after chemotherapy administration: the MEDEA trialEUCTR2011-004446-17-NLVU University Medical Center Amsterdam450
已完成
3 期
MEtoclopramide, DExamethasone or Aloxi (palonosetron) for the prevention of delayed chemotherapy-induced nausea and vomiting in moderately emetogenic non-AC-based chemotherapy: the MEDEA trialalle vormen van solide tumorenchemotherapy induced nausea and vomitingnausea and vomiting caused by chemotherapyNL-OMON44716Vrije Universiteit Medisch Centrum450
已完成
不适用
comparision between Aprepitant and Dexamethasone For Preventing Postoperative Nausea And Vomiting In Breast Cancer PatientsCTRI/2014/12/005333AIIMS160
进行中（未招募）
不适用
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failureThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-ATWilhelminen Krebsforschung GmbH50
进行中（未招募）
1 期
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure - LDThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-SKWilhelminen Krebsforschung GmbH50